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Abstract
Background: Delayed gastric emptying (DGE) is a frequent cause of morbidity, prolonged hospital
stay and readmission after a pancreaticoduodenectomy (PD). We sought to evaluate predictive peri-
operative factors for DGE after a PD.
Methods: Four hundred and sixteen consecutive patients who underwent a PD at our tertiary referral
centre were identified. Univariate and multivariate (MV) logistic regression models were used to assess
peri-operative factors associated with the development of clinically significant DGE and a post-opera-
tive pancreatic fistula (POPF).
Results: DGE occurred in 24% of patients (n = 98) with Grades B and C occurring at 13.5% (n = 55)
and 10.5% (n = 43), respectively. Using MV regression, a body mass index (BMI) ≥35 [odds ratio (OR)
= 3.19], operating room (OR) length >5.5 h (OR = 2.72) and prophylactic octreotide use (OR = 2.04)
were independently associated with an increased risk of DGE. DGE patients had a significantly longer
median hospital stay (12 versus 7 days), higher 90-day readmission rates (32% versus 18%) and an
increased incidence of a pancreatic fistula (59% versus 27%). When controlling for POPF, only OR
length >5.5 h (OR 2.73) remained significantly associated with DGE.
Conclusions: DGE remains a significant cause of morbidity, increased hospital stay and readmission
after PD. Our findings suggest patients with a BMI ≥35 or longer OR times have a higher risk of DGE
either independently or through the development of POPF. These patients should be considered for
possible enteral feeding tube placement along with limited octreotide use to decrease the potential risk
and consequences of DGE.
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Introduction
After a pancreaticoduodenectomy (PD), delayed gastric empty-
ing (DGE) is one of the most common causes of post-opera-
tive morbidity affecting 15–40% of patients.1–5 DGE is strongly
correlated with an increased hospital length of stay, cost, read-
mission and patient dissatisfaction.6–10 New approaches in sur-
gical techniques, medical therapies and post-operative
interventions have been successful at reducing post-operative
mortality to <3%;2,7,11,12 however, these advances have not
significantly reduced the number of patients who continue to
suffer from the complications of DGE.
Although there have been several studies investigating the
aetiology, associations and complications of DGE, no uni-
formly accepted definition for DGE after pancreatic surgery
existed prior to 2007. In 2007, owing to the growing need for
a consensus to evaluate the incidence and risk factors for the
development of DGE, the International Study Group of
Pancreatic Surgery (ISGPS) developed a standardized definition
for classifying the severity of DGE into mild, moderate and
severe based on nasogastric tube necessity and time-to-tolerate
solid food intake. Moderate (Class B) DGE includes nasogastric
tube (NGT) replacement between post-operative day 8 and 14
or an inability to tolerate solid oral intake by post-operative
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day 14. Severe (Class C) DGE includes nasogastric tube (NGT)
replacement after postoperative day 14 or inability to tolerate
solid oral intake by postoperative day 21. Even after this defi-
nition was accepted, there have been a paucity of studies inves-
tigating pre- and intra-operative factors that may help predict
DGE in the hope of preventing its development and/or prepar-
ing for its consequences.
The objective of this study was to identify pre- and peri-
operative factors associated with the development of DGE after
a PD at our tertiary referral centre during the last 12 years
with the aim of being able to predict those patients at highest
risk and therefore develop interventional strategies to prevent
DGE before its occurrence.
Patients and methods
Data source and cohort selection
Patients aged 18 years and older who underwent a PD at Vander-
bilt University Medical Center between July 2000 and December
2012 were identified from a retrospective pancreatic patient
database. Pre-operative variables collected included patient
demographics, comorbidities and other patient-specific factors.
Intra-operative variables collected included estimated blood loss
(EBL), transfusion need, details of the surgical resection and
reconstruction, operative time, tumour size and prophylactic
octreotide use. DGE grade was classified as per the recom-
mended ISGPS consensus definition as previously discussed. For
our study, we defined clinically significant DGE as ISGPS class B
or C as previously discussed. Data on the incidence and associa-
tions of post-operative pancreatic fistula (POPF) after a PD were
also obtained and classified according to the International Study
Group on Pancreatic Fistula (ISGPF) recommended guidelines
with Grade B and C POPF considered clinically significant.13
Post-operative management
Patients undergoing PD were entered on a clinical pathway for
the management of their post-operative course. NGTs placed
in the operating room were discontinued on post-operative
day 1 if patients were not nauseated and if NGT output was
minimal. They were then advanced to clear liquids and upon
return of bowel function, advanced to a low-fat diet. Metoclo-
pramide (Reglan) was routinely started on post-operative day
3 if not contraindicated. Erythromycin, however, was not given
routinely.
Statistical analysis
Univariate comparisons between patient cohorts were per-
formed using chi-squared or Fisher’s exact tests. Forward selec-
tion and backward elimination stepwise multivariate (MV)
logistic regression models were constructed to estimate the
effects of pre- and intra-operative factors on the incidence of
DGE. All variables were selected a priori, and variables with P
< 0.30 were included as independent factors in the final MV
regression model. Univariate associations between the inci-
dence of DGE and length of hospital stay, 90-day readmission
and pancreatic fistulas/leaks were also performed. Analyses
were performed using STATA 13.1 statistical software (Stata
Corporation, College Station, TX, USA).
This study was approved by the Institutional Review Board
of the VUMC Human Research Protection Program.
Results
Cohort
In our pancreatic database, a total of 416 patients were identified
to have undergone a PD from July 2000 to December 2012 and
were included in the cohort. Of these patients, 153 (37%)
patients were found to have DGE (all grades). A total of 98
patients (24%) were diagnosed with Grade B (55 patients,
13.2%) or Grade C (43 patients, 10.3%) DGE. For the purposes
of this study, we defined these Grade B and C patients as having
clinically significant DGE and form the basis of our analysis.
Demographics
Demographic comparisons of those patients having clinically
significant DGE versus those who did not are shown in Table 1a.
The only factor showing a statistical difference between groups
was race with a higher percentage of Caucasians in the DGE
group than the non-DGE group (96% versus 87%, P = 0.02).
Other factors, including mean age, gender and the incidence of
malignancy, did not significantly differ between groups.
Approximately half of the patients were smokers, but this did
not differ between groups.
Patient co-morbidities
In regards to patient co-morbidities, patients with DGE had a
significantly higher American Society of Anesthesiologists
(ASA) class (Table 1a). In addition, a higher percentage of
DGE patients had a body mass index (BMI) of greater than or
equal to 35 (15% versus 7%, P = 0.02). Although the incidence
of diabetes mellitus (DM) and coronary artery disease (CAD)
was prevalent in our cohort (20–25% and 17–20%), the
incidence did not differ between the groups.
Pre-operative characteristics
As shown in Table 1a, both the DGE and non-DGE patient
groups had similar pre-operative patient characteristics includ-
ing the use of a biliary stent, serum albumin <4.0 gm/dl, the
use of neoadjuvant therapy, the incidence of gastric outlet
obstruction and pre-operative weight loss. Although the mean
serum bilirubin (mg/dl) appeared to be lower in the DGE
group (2.7  5.2 versus 3.3  5.9, P = 0.15), this was not
statistically significant.
Intra- and post-operative characteristics
Details with regards to intra- and post-operative factors in
both groups are shown in Table 1b. Patients with DGE were
more likely to have had an operative time over 5.5 h as
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Table 1 (a) Univariate analysis of pre-operative factors on delayed
gastric emptying (DGE). (b) Univariate analysis of intra- and post-
operative factors on DGE (Grade B or C)
Variable No DGE
(n = 318)
n (%) or
mean  SD
DGEa
(n = 98)
n (%) or
mean  SD
P-value
(a)
Demographics
Mean age (years  SD) 61.2  13.7 62.2  13.6 0.89
Gender 0.21
Male (n) 152 (48) 54 (55)
Female (n) 166 (52) 44 (45)
Race 0.02
White 277 (87) 94 (96)
Black/other 40 (13) 4 (4)
Malignancy 0.11
No 87 (27) 35 (36)
Yes 231 (73) 63 (64)
Mean tumour size
(cm  SD)
3.0  1.9 2.9  1.7 0.22
Patient comorbidities
ASA class 0.04
2 87 (27) 16 (16)
3 205 (65) 77 (79)
4 25 (8) 5 (5)
BMI 0.02
<35 295 (93) 83 (85)
≥35 23 (7) 15 (15)
DM 0.63
No 238 (75) 78 (80)
Yes 80 (25) 20 (20)
CAD 0.40
No 265 (83) 78 (80)
Yes 53 (17) 20 (20)
CHF 0.41
No 302 (95) 95 (97)
Yes 16 (5) 3 (3)
Cirrhosis 0.38
No 315 (99) 96 (98)
Yes 3 (1) 2 (2)
Smoking history 0.20
No 169 (54) 45 (46)
Yes < 5 pack-years 53 (17) 24 (24)
Yes > 5 pack-years 92 (29) 29 (30)
Patient characteristics
Pre-op Biliary Stent 0.31
No 160 (51) 55 (57)
Yes 155 (49) 42 (43)
Table 1 Continued
Variable No DGE
(n = 318)
n (%) or
mean  SD
DGEa
(n = 98)
n (%) or
mean  SD
P-value
Albumin (gm/dl) < 4.0 0.51
No 155 (49) 44 (45)
Yes 163 (51) 54 (55)
Pre-op bilirubin
(mg/dl  SD)
3.3  5.9 2.7  5.2 0.15
Pre-op Chemotherapy 0.25
No 301 (95) 90 (92)
Yes 16 (5) 8 (8)
Pre-op radiation 0.77
No 306 (97) 94 (96)
Yes 11 (3) 4 (4)
Gastric outlet obstruction 0.94
No 263 (83) 81 (83)
Yes 54 (17) 17 (17)
Pre-op weight loss 0.30
No 184 (58) 51 (52)
Yes 133 (42) 47 (48)
(b)
Whipple reconstruction 0.06
Standard 125 (39) 32 (33)
Pylorus-Preserving
(PPPD)
51 (16) 26 (26)
PPPD + Pyloroplasty 142 (45) 40 (41)
Path of reconstruction 0.41
Antecolic 187 (79) 53 (73)
Retrocolic 45 (19) 19 (26)
Unknown 5 (2) 1 (1)
PJ Stent 0.25
No 164 (52) 44 (45)
Yes 154 (48) 54 (55)
Vascular resection 0.82
No 263 (83) 82 (84)
Yes 55 (17) 16 (16)
Estimated blood loss (cc) 632  576 718  635 0.23
Blood products given 0.40
No 222 (70) 64 (65)
Yes 96 (30) 34 (35)
Operative time (h) 0.05
<5.5 122 (38) 27 (28)
>5.5 196 (62) 71 (72)
Prophylactic Octreotide 0.11
No 219 (69) 59 (60)
Yes 99 (31) 39 (40)
a
ISPGS Grade B or C.
ASA,AmericanSocietyofAnesthesiologists;BMI,bodymassindex;DM,dia-
betesmellitus;CAD,coronaryarterydisease;CHF,congestiveheart failure.
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compared with those without DGE (72% versus 62%, P =
0.05). Patients who received octreotide prophylactically (intra-
operative  post-operative) tended to develop DGE more fre-
quently (40% versus 31%); however, this was not statistically
significant in the univariate analysis (P = 0.11). Other factors,
including the type of reconstruction, the use of a pancreatico-
jejunostomy (PJ) stent, vascular resection, EBL and the use of
blood transfusions, were similar in both groups.
Peri-operative factors associated with DGE
All variables were added into the model sequentially using for-
ward selection stepwise multivariable regression modelling.
Those variables with P < 0.30 by MV regression were used in
the final model. Variables included in the final model included
malignancy, albumin < 4.0, smoking, race, operating room
(OR) time >5.5 h, prophylactic octreotide use and a BMI ≥35.
Of these, a BMI ≥35 [OR = 3.19; 95% confidence interval (CI)
1.24–8.18], operating room length >5.5 h (OR = 2.72; 95% CI
1.37–5.39) and prophylactic octreotide use (OR = 2.04; 95%
CI 1.09–3.80) were independently associated with an increased
risk of DGE as shown in Fig. 1. None of the other variables
tested were associated with an increased risk of DGE.
DGE and other associated complications
Patients with DGE had a significantly higher rate of post-opera-
tive pancreatic fistulae (POPF) as compared with those without
DGE (59% versus 27% P < 0.001). This difference was particu-
larly pronounced when looking at Grade B and Grade C POPF
(52% versus 11%, P < 0.001) as shown in Fig. 2. Patients with
clinically significant DGE also had a significantly longer median
hospital stay [12 days interquartile range (IQR) = 6–17] versus 7
days (IQR = 3–8), P < 0.001] and a higher rate of 90-day read-
mission (32% versus 18%, P = 0.004) as shown in Fig. 3.
Post-operative pancreatic fistula
As there was a very strong relationship between the develop-
ment of DGE and POPF, we investigated the possible role of
POPF as a confounder and possible causal factor in the devel-
opment of DGE. When the development of POPF was added
to the forward stepwise MV regression model for the develop-
ment of DGE, the only factors that were significantly associated
with DGE included operating length length >5.5 h (OR 2.73,
95% CI 1.32–5.64) and POPF (OR 10.4, 95% CI 5.1–21.4).
When controlling for POPF, therefore, a BMI ≥35 and the use
of octreotide were no longer associated with the development
of DGE (data not shown).
In agreement with these results, when a stepwise MV regres-
sion modelling for the development of DGE was constructed
in those patients without a clinically significant leak (n = 318),
the only significant factors associated with the development of
DGE was a operative time >5.5 h (OR 3.73, 95% CI 1.39–9.95,
data not shown).
Malignancy
Albumin < 4.0
Smoking
Race
OR time > 5.5 h
Octreotide
BMI ≥ 35
Odds ratio
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Figure 1 Forest plot, multivariate logistic regression analysis of
factors associated with delayed gastric emptying. OR, operating
room; BMI, body mass index
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Figure 2 Patients with delayed gastric emptying (DGE) had a
significantly higher rate of post-operative pancreatic fistulae
(POPF) as compared with those without DGE (59% versus 27% P
< 0.001). This was most pronounced when looking at clinically
significant (Grade B and C) POPF with an incidence of 52% in
patients with DGE versus those without DGE (11%, P < 0.0001)
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Figure 3 Patients with clinically significant delayed gastric
emptying (DGE) had a significantly longer median hospital length
of stay(LOS) [12 days (IQR=6–17) versus 7 days (IQR=3–8), P <
0.001] and a higher rate of 90-day readmission (32% versus 18%,
P = 0.004)
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Discussion
This compilation of 416 patients from a single institution
allows for a thorough analysis of patients after a PD and risk
factors for the development of DGE according to the recent IS-
GPS definition. The overall incidence of DGE in this study was
37%, with 24% having Grades B or C DGE, consistent with
other reports.1–3,5 This study, unlike most prior, classifies the
severity of DGE based on the ISGPS definition. The present
study also revealed significant independent pre- and peri-oper-
ative risk factors for developing clinically significant DGE,
including a BMI ≥35 (OR 3.19), operative time >5.5 h (OR
2.72) and the prophylactic use of octreotide (OR 2.04). Similar
to the prior series, DGE was also associated with a significantly
longer median hospital stay, a higher 90-day readmission rate
and an increased incidence of POPF.6,7,9,10 When investigating
possible confounders for the association of these factors with
the development of DGE, we found that the development of a
POPF was the most significant factor in predicting DGE.
The pathogenesis of DGE is still largely unclear. Current
hypotheses include pylorospasm secondary to denervation of
the vagus nerves, ischaemia or congestion secondary to vascu-
lar compromise, and acute changes in plasma gastrointestinal
hormone (specifically motilin) levels.14 In addition, prior
reports show conflicting results on pre-operative variables that
may contribute to DGE, including age, gender, race and gastric
outlet obstruction.5,10,15–17 In the present study, however, these
factors did not appear to play a role. Operative technique has
in many studies been suggested to play a role in the develop-
ment of DGE. The standard Whipple procedure versus the
pylorus-preserving pancreaticoduodenectomy,3,18–22 antecolic
versus retrocolic gastric/duodenal reconstruction,4,15,23 pancre-
aticogastrostomy versus pancreaticojejunostomy reconstruc-
tion,24,25 PJ stent placement26,27 and portal vein resection28
have been evaluated in many studies. However, the results are
mixed and many of the studies are small cohorts with retro-
spective analyses that lack consistency in the definition of
DGE. In the present study, operative technique including pres-
ervation of the pylorus, antecolic versus retrocolic reconstruc-
tion as well as vascular resection or the use of a PJ stent were
not associated with differences in the incidence of DGE.
Comorbidities including DM, CAD, congestive heart failure
(CHF), cirrhosis and smoking history did not show a statisti-
cally significant correlation with the development of DGE and
were consistent with prior studies.1,3,5,10 The present study
revealed that patients with severe obesity or greater, defined by
a BMI of 35 or higher, was strongly associated with an
increased development of DGE by multivariate analysis. There
have been studies investigating the relationship between obesity
and gastric emptying in both non-operative29,30 and operative
patients;1,10,17,31 however, the present study is, to our knowl-
edge, the first to show a relationship between BMI and DGE
after a PD. As a BMI ≥35 was also associated with a significant
risk of developing a POPF, we sought to investigate whether
obesity directly led to an increase incidence of DGE or indi-
rectly by increasing POPF. In the MV analysis of patients with-
out a POPF as well as the MV analysis with POPF included in
the model we found that a BMI ≥35 was not associated with
the development of DGE, suggesting that the increase in DGE
was actually secondary to a POPF and not as a result of an
increased BMI. Nevertheless, as the development of a POPF is
not known pre- or intra-operatively, it would still be impor-
tant to counsel these patients that they may be at a higher risk
of DGE (as well as a POPF) after a PD.
The only operative factor in the current study that was signifi-
cantly associated with the development of DGE was operative
time, as defined by time from incision to closure of the wound,
of greater than 5.5 h. This was also the only factor to show sig-
nificance for the development of DGE when POPF was added to
the model as well as in patients who do not develop a POPF.
Longer OR times than 5.5 h did not further increase the risk of
DGE (data not shown). Presumably, increased complexity of the
operation contributed to an increased OR time; however, other
factors associated with increased complexity including EBL, the
need for blood transfusions, as well as vascular resections were
not associated with the development of DGE as suggested in
some prior studies.28,32 Prior studies have evaluated operative
time for an association with DGE; however, this is the first study
to suggest that operative time is independently associated with a
risk DGE after PD.10,22
The final factor shown to be associated with DGE in the cur-
rent study was the use of prophylactic octreotide (Sandostatin).
Octreotide is a somatostatin analogue shown to inhibit growth
hormone, insulin and glucagon. It has been reported that even a
subcutaneous administration of a single dose of octreotide can
induce a marked delay in the gastric emptying of healthy indi-
viduals.33 Some prior studies have shown that octreotide use
does not have a correlation with DGE,34,35 and a single study
consisting of a small cohort of patients (n = 23) showed a much
higher incidence of DGE with the use of prophylactic somato-
statin (91% versus 25%).36,37 Similar to the case of BMI, how-
ever, the use of a prophylactic octreotide was significantly
associated with the incidence of a POPF. As we only use a pro-
phylactic octreotide in those patients considered to be a higher
risk of a leak (including those with small pancreatic ducts and a
soft pancreatic texture), this association is not surprising. It is
interesting to note, however, that in the absence of a POPF, the
use of octreotide did not increase the risk of DGE.
Post-operative complications have also been implicated as a
leading factor in the development of DGE after a PD. Intra-
abdominal complications including POPF, intra-abdominal
abscess, post-operative sepsis, the need for reoperation, pancre-
atitis and pancreatic fibrosis have been associated with the
development of DGE.1,10,16,17,19 Some studies have even
suggested that DGE does not occur in the absence of other
post-operative complications.3 Data from thus study are in
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agreement with these findings as POPF was the most signifi-
cant factor associated with DGE. Measures to try to reduce
POPF may in fact, therefore, reduce the incidence of DGE.
Additional studies investigating a possible causal relationship
between POPF and DGE are warranted, however, before mak-
ing final conclusions.
As with all retrospective studies, our study has several limi-
tations including incomplete documentation, interpretation
bias, and difficulty establishing cause and effect. In addition,
our study is limited in that it is a single-institutional study
with a relatively small sample size, causing our analysis poten-
tially to lack sufficient power to detect some significant factors
associated with DGE. In addition, despite the utilization of
clinical pathways, variability in the management of patients
after a PD most certainly exist and may account for some of
the observed differences.
In conclusion, our study confirms that despite improved
surgical mortality after a PD, DGE remains a significant clini-
cal problem. DGE is associated with significant other sequelae
including significant increases in hospital length of stay and re-
admission rates compared with those who did not develop
DGE. These associated sequelae may be as a direct result of
DGE or as a result of associated complications of DGE includ-
ing POPF, particularly as the development of POPF is one of
the strongest predictors of the development of DGE. Indeed
patients with the highest risk of pancreatico-jejunostomy leak
may be those with a higher BMI, longer OR times, and in
which prophylactic octreotide is used, are also at the highest
risk of DGE (as well as POPF). Strategies to combat DGE after
PD should also therefore focus on reducing the formation of
POPF. In these patients deemed to be at higher risk of DGE as
well as POPF, enteral feeding access (i.e. intra-operatively
placed nasojejunal post-anastomotic feeding tubes or jejunosto-
my tubes) should be considered. Additional studies validating
our findings are also warranted, particularly in a prospective
manner and with stratification of the presence or absence of
POPF, in order to further elucidate the causes and mechanisms
of DGE to allow for potential interventions to decrease this
major source of morbidity following pancreaticoduodenectomy.
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